205 related articles for article (PubMed ID: 30547371)
21. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
Younossi ZM; Stepanova M; Lawitz EJ; Reddy KR; Wai-Sun Wong V; Mangia A; Muir AJ; Jacobson I; Djedjos CS; Gaggar A; Myers RP; Younossi I; Nader F; Racila A
Am J Gastroenterol; 2019 Oct; 114(10):1636-1641. PubMed ID: 31464743
[TBL] [Abstract][Full Text] [Related]
22. Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.
Maahs S; Leclair D; Gomez-Mancilla B; Kiluk BD; Muthusamy VS; Banerjee PS; Dasgupta S; Waye KM
Front Psychiatry; 2024; 15():1230699. PubMed ID: 38487570
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
25. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
[TBL] [Abstract][Full Text] [Related]
26. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
27. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
Wessels DH; Rosenberg Z
World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
[TBL] [Abstract][Full Text] [Related]
28. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
30. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
31. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
32. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.
Eguchi Y; Wong G; Lee EI; Akhtar O; Lopes R; Sumida Y
JGH Open; 2020 Oct; 4(5):808-817. PubMed ID: 33102749
[TBL] [Abstract][Full Text] [Related]
34. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with non-alcoholic steatohepatitis (NASH) in real life.
Serfaty L
Liver Int; 2018 Feb; 38 Suppl 1():52-55. PubMed ID: 29427486
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy for NASH: Current and emerging.
Konerman MA; Jones JC; Harrison SA
J Hepatol; 2018 Feb; 68(2):362-375. PubMed ID: 29122694
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
38. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
39. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
[TBL] [Abstract][Full Text] [Related]
40. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis.
Henry ZH; Argo CK
Gastroenterol Clin North Am; 2020 Mar; 49(1):45-62. PubMed ID: 32033764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
